What are the indications, dosing regimen, contraindications, drug interactions, and adverse effects of the new drug Journavx (suzetrigine)?

Journavx (Suzetrigine): A Novel Non-Opioid Analgesic for Acute Pain

Journavx (suzetrigine) is the first FDA-approved selective NaV1.8 sodium channel inhibitor indicated for moderate to severe acute pain in adults, offering a non-opioid alternative with demonstrated efficacy comparable to hydrocodone/acetaminophen in postoperative settings. 1

Mechanism of Action

Suzetrigine works by selectively inhibiting voltage-gated sodium channel 1.8 (NaV1.8), which is exclusively expressed in peripheral pain-sensing neurons and not in the central nervous system 2. The drug binds to the channel's second voltage sensing domain (VSD2) to stabilize the closed state, resulting in tonic inhibition that reduces pain signal transmission 2. This peripheral-only mechanism explains the absence of CNS side effects and addictive potential seen with opioids 2.

Indications

Journavx is FDA-approved specifically for the treatment of moderate to severe acute pain in adults. 1 Clinical trials demonstrated efficacy in postoperative pain following abdominoplasty and bunionectomy, as well as broader applicability across various surgical and non-surgical acute pain conditions 3, 4.

Dosing Regimen

Standard Dosing (Normal Hepatic Function)

• Starting dose: 100 mg orally on an empty stomach (at least 1 hour before or 2 hours after food); clear liquids permitted 1
• Maintenance dosing: Beginning 12 hours after the starting dose, take 50 mg orally every 12 hours with or without food 1
• Duration: Use for the shortest duration consistent with treatment goals; not studied beyond 14 days 1
• Administration: Swallow tablets whole; do not chew or crush 1

Dosing in Hepatic Impairment

Moderate hepatic impairment (Child-Pugh Class B): 1

• Starting dose: 100 mg orally on empty stomach
• Doses 2-4: 50 mg every 12 hours (starting 12 hours after initial dose)
• Dose 5 and beyond: 50 mg every 24 hours (reduced frequency due to increased drug exposure)

Severe hepatic impairment (Child-Pugh Class C): Avoid use 1

Mild hepatic impairment (Child-Pugh Class A): Use standard dosing 1

Dosing with CYP3A Inhibitors

Moderate CYP3A inhibitors: 1

• Starting dose: 100 mg orally on empty stomach
• Doses 2-4: 50 mg every 12 hours
• Dose 5 and beyond: 50 mg every 24 hours
• Avoid grapefruit-containing foods or drinks during treatment 1

Missed Dose Management

Standard dosing schedule: 1

• If one dose missed: Take as soon as possible, then resume regular schedule
• If two or more doses missed: Take 100 mg, then resume regular schedule

Modified dosing (hepatic impairment or moderate CYP3A inhibitors): 1

• If next scheduled dose is within 6 hours: Skip next dose and resume subsequent doses at recommended time
• Otherwise: Take missed dose as soon as possible

Contraindications

Concomitant use with strong CYP3A inhibitors is absolutely contraindicated. 1 Strong CYP3A inhibitors significantly increase suzetrigine and its active metabolite (M6-SUZ) exposures, leading to increased risk of adverse reactions 1.

Drug Interactions

CYP3A Inhibitors

• Strong CYP3A inhibitors: Contraindicated (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir) 1
• Moderate CYP3A inhibitors: Require dose reduction as outlined above 1
• Grapefruit: Avoid all grapefruit-containing products 1

CYP3A Inducers

Avoid concomitant use with strong or moderate CYP3A inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort), as they may reduce suzetrigine efficacy 1.

CYP3A Substrates

Suzetrigine is a CYP3A inducer and may reduce concentrations of CYP3A substrates 1. For sensitive CYP3A substrates or those where minimal concentration changes lead to loss of efficacy, refer to the substrate's prescribing information for dosing adjustments when initiating or discontinuing Journavx. 1

Hormonal Contraceptives

Patients using hormonal contraceptives containing progestins other than levonorgestrel or norethindrone must use additional non-hormonal contraception (e.g., condoms) or switch to alternative contraceptives during Journavx treatment and for 28 days after discontinuation. 1 This is due to suzetrigine's CYP3A induction potentially reducing contraceptive efficacy 1.

Adverse Effects

Common Adverse Reactions

The most common adverse reactions (greater incidence than placebo) in clinical trials were 1:

• Pruritus
• Muscle spasms
• Increased creatine phosphokinase
• Rash

Safety Profile

In pooled phase 3 trials (n=874), discontinuation due to adverse events occurred in only 0.6% of suzetrigine-treated patients 1. Most adverse events were mild (27.7%) to moderate (8.2%) in severity 4. Notably, suzetrigine demonstrated no CNS side effects, cardiovascular effects, or evidence of addictive potential or dependence in comprehensive nonclinical and clinical assessments. 2

Isolated Case Reports

One case report documented patient-reported paresthesia following suzetrigine administration for refractory postoperative pain 5. This represents an unanticipated side effect not prominently featured in clinical trial data and warrants monitoring as real-world use expands 5.

Clinical Efficacy

Postoperative Pain

In two phase 3 randomized controlled trials, suzetrigine demonstrated statistically significant and clinically meaningful pain reduction compared to placebo 3:

• Abdominoplasty trial: Least squares mean difference in SPID48 (time-weighted sum of pain intensity difference 0-48 hours) was 48.4 (95% CI: 33.6-63.1; P<0.0001) 3
• Bunionectomy trial: Least squares mean difference in SPID48 was 29.3 (95% CI: 14.0-44.6; P=0.0002) 3

Time to clinically meaningful pain relief (≥2-point reduction in numeric pain rating scale) was significantly faster with suzetrigine versus placebo: 119 minutes vs. 480 minutes after abdominoplasty and 240 minutes vs. 480 minutes after bunionectomy 3.

Comparison to Opioids

Neither trial achieved superiority of suzetrigine versus hydrocodone bitartrate/acetaminophen (5/325 mg) on the primary endpoint. 3 Pain reduction with suzetrigine was similar to hydrocodone/acetaminophen, but not superior 3, 6. This suggests suzetrigine may be less potent than opioid combinations for moderate to severe postoperative pain, though it offers advantages in safety profile and lack of addiction potential 6.

Broad Applicability

A phase 3 single-arm study (n=256) evaluated suzetrigine across diverse surgical and non-surgical acute pain conditions 4. 83.2% of participants rated suzetrigine's effectiveness as good, very good, or excellent on patient global assessment. 4

Special Populations

Hepatic Impairment

Patients with moderate hepatic impairment have higher systemic exposures of suzetrigine and M6-SUZ, increasing the risk of adverse reactions 1. Dose reduction is mandatory in this population 1. Avoid use entirely in severe hepatic impairment (Child-Pugh Class C). 1

Renal Impairment

The FDA label does not specify dosage adjustments for renal impairment 1, suggesting renal function does not significantly impact suzetrigine pharmacokinetics based on available data.

Clinical Considerations and Pitfalls

Duration of Use

Journavx is approved only for acute pain and has not been studied beyond 14 days. 1 Its role in chronic pain management remains undefined and requires further investigation 6.

Severity of Pain

Current evidence supports suzetrigine's use primarily for minimally to moderately painful ambulatory procedures 6. Efficacy in more severe postoperative pain contexts remains unclear and may be inferior to opioid combinations. 6

Drug Interaction Vigilance

Given suzetrigine's role as a CYP3A inducer, clinicians must carefully review all concomitant medications, particularly 1:

• Immunosuppressants (e.g., tacrolimus, cyclosporine)
• Anticoagulants (e.g., apixaban, rivaroxaban)
• Chemotherapeutic agents
• Antiretrovirals
• Hormonal contraceptives

Food Restrictions

The starting dose must be taken on an empty stomach to ensure proper absorption 1. Failure to adhere to this requirement may compromise initial pain control. Maintenance doses can be taken with or without food 1.

Cost Considerations

As a newly approved first-in-class medication, cost and insurance coverage patterns are still emerging 7. Clinicians should verify formulary status and patient out-of-pocket costs before prescribing 7.